Literature DB >> 16091225

Primary HIV Infection.

Joanne Stekler1, Ann C Collier.   

Abstract

Primary HIV infection refers to the events surrounding acquisition of HIV infection. It is associated with a nonspecific clinical syndrome that occurs 2 to 4 weeks after exposure in 40% to 90% of individuals acquiring HIV. Patients identified before seroconversion often have very high plasma HIV RNA titers that, without treatment, gradually decrease to reach a set point. Treatment of primary HIV infection with highly active antiretroviral therapy does not prevent establishment of chronic infection. However, very early therapy could potentially decrease the viral set point, prevent viral diversification, preserve immune function, improve clinical outcomes, and decrease secondary transmission. These benefits have not yet been definitely demonstrated. Transmission of viral strains with decreased susceptibility to antiviral drugs has led to recommendations for resistance testing in primary infection before initiation of therapy. Immunomodulators and vaccines are also under study as adjuvant therapy for treatment of primary HIV infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16091225     DOI: 10.1007/s11904-004-0010-2

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.495


  48 in total

1.  Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection.

Authors:  L K Musey; J N Krieger; J P Hughes; T W Schacker; L Corey; M J McElrath
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

2.  Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS.

Authors:  M M Berrey; T Schacker; A C Collier; T Shea; S J Brodie; D Mayers; R Coombs; J Krieger; T W Chun; A Fauci; S G Self; L Corey
Journal:  J Infect Dis       Date:  2001-04-24       Impact factor: 5.226

3.  Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection.

Authors:  D Smith; M M Berrey; M Robertson; D Mehrotra; M Markowitz; L Perrin; N Clumeck; A Lazzarin; B Burckhardt; R Weber; L Corey; D A Cooper
Journal:  J Infect Dis       Date:  2000-08-17       Impact factor: 5.226

4.  Clinical and epidemiologic features of primary HIV infection.

Authors:  T Schacker; A C Collier; J Hughes; T Shea; L Corey
Journal:  Ann Intern Med       Date:  1996-08-15       Impact factor: 25.391

5.  Transmission of antiretroviral-drug-resistant HIV-1 variants.

Authors:  S Yerly; L Kaiser; E Race; J P Bru; F Clavel; L Perrin
Journal:  Lancet       Date:  1999-08-28       Impact factor: 79.321

6.  Biological and virologic characteristics of primary HIV infection.

Authors:  T W Schacker; J P Hughes; T Shea; R W Coombs; L Corey
Journal:  Ann Intern Med       Date:  1998-04-15       Impact factor: 25.391

7.  Initiation of therapy during primary HIV type 1 infection results in a continuous decay of proviral DNA and a highly restricted viral evolution.

Authors:  A C Karlsson; M Birk; S Lindbäck; H Gaines; J E Mittler; A Sönnerborg
Journal:  AIDS Res Hum Retroviruses       Date:  2001-03-20       Impact factor: 2.205

8.  Time trends in primary HIV-1 drug resistance among recently infected persons.

Authors:  Robert M Grant; Frederick M Hecht; Maria Warmerdam; Lea Liu; Teri Liegler; Christos J Petropoulos; Nicholas S Hellmann; Margaret Chesney; Michael P Busch; James O Kahn
Journal:  JAMA       Date:  2002-07-10       Impact factor: 56.272

9.  Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.

Authors:  T W Chun; D Engel; M M Berrey; T Shea; L Corey; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

10.  Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection.

Authors:  M Altfeld; E S Rosenberg; R Shankarappa; J S Mukherjee; F M Hecht; R L Eldridge; M M Addo; S H Poon; M N Phillips; G K Robbins; P E Sax; S Boswell; J O Kahn; C Brander; P J Goulder; J A Levy; J I Mullins; B D Walker
Journal:  J Exp Med       Date:  2001-01-15       Impact factor: 14.307

View more
  5 in total

Review 1.  Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS.

Authors:  Maria M Bednar; Christa Buckheit Sturdevant; Lauren A Tompkins; Kathryn Twigg Arrildt; Elena Dukhovlinova; Laura P Kincer; Ronald Swanstrom
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

2.  Sexually transmitted infections among patients with acute HIV in North Carolina.

Authors:  Sandra I McCoy; Joseph J Eron; Joann D Kuruc; Ronald P Strauss; Pia D M Macdonald; Susan A Fiscus; John Barnhart; Christopher D Pilcher; Peter A Leone; William C Miller
Journal:  Sex Transm Dis       Date:  2009-06       Impact factor: 2.830

3.  A sensitive real-time PCR based assay to estimate the impact of amino acid substitutions on the competitive replication fitness of human immunodeficiency virus type 1 in cell culture.

Authors:  Yi Liu; Sarah Holte; Ushnal Rao; Jan McClure; Philip Konopa; J Victor Swain; Erinn Lanxon-Cookson; Moon Kim; Lennie Chen; James I Mullins
Journal:  J Virol Methods       Date:  2012-11-29       Impact factor: 2.014

4.  Impact of mutations in highly conserved amino acids of the HIV-1 Gag-p24 and Env-gp120 proteins on viral replication in different genetic backgrounds.

Authors:  Yi Liu; Ushnal Rao; Jan McClure; Philip Konopa; Siriphan Manocheewa; Moon Kim; Lennie Chen; Ryan M Troyer; Denis M Tebit; Sarah Holte; Eric J Arts; James I Mullins
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

Review 5.  HIV and neurocognitive dysfunction.

Authors:  Serena Spudich
Journal:  Curr HIV/AIDS Rep       Date:  2013-09       Impact factor: 5.071

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.